Program for 3rd EAU North Eastern European Meeting looks promising

The European Association of Urology (EAU) regularly organises regional meetings in Europe, such as the upcoming North Eastern European Meeting (NEEM). These are platforms where new clinical or experimental work from the region is presented to an international audience. Young urologists are especially invited to participate.

The 3rd NEEM meeting will take place in the Radisson SAS Hotel in Szczecin, Poland. Professor Andrzej Sikorski (Szczecin, PL), chairman of the meeting: "We were happy to receive 108 high-quality abstracts, a great contribution from dedicated researchers from all over the region. There were contributions from countries within the region, such as Lithuania, Poland and Russia, but also from countries further away, such as Turkey. This proves the NEEM is truly international".

On Friday, 11 September the meeting starts with an update on Penile Surgery, followed by Early diagnosis of prostate cancer - risks and benefits in the afternoon. New data on the subject are presented by Prof M. Graefen, Hamburg (DE).

Poster sessions on Prostate Cancer, BPH and Prostate Biopsy and Bladder cancer are organised in the morning and the subjects Overactive bladder, Incontinence, Prostatitis and Renal disease are covered in the afternoon.

The day is concluded by a debate entitled Androgen supplementation in aging males
chaired by Prof B. Darewicz, Bialystok (PL) and a lecture - sponsored by GE Healthcare - on Improving TUR-B with fluorescence cystoscopy

The Saturday programme looks equally promising with Prostate cancer - the burden of treatment - including a presentation about the management of ED by Prof Sikorski - as the main subject in the morning, followed by the State-of-the-art lecture 'What the urologist needs to know in female stress incontinence' delivered by Professor Walter Artibani, Padua (IT). The programme is continued with poster sessions (External genital and Stones and Reconstruction) and completed with a debate on chemoprevention of prostate cancer, chaired by Prof Graefen, Hamburg (DE). The benefits are defended by Prof Marberger, Vienna (AT) and the risks are highlighted by Professor Artibani, Padua (IT)

Source: European Association of Urology